Publications by authors named "V A Livolsi"
Article Synopsis
- - NIFTP is a newly classified thyroid neoplasm that has replaced the previous diagnosis of a certain type of thyroid cancer, with varying adoption rates noted across different global regions.
- - A survey of 48 pathologists showed a 94% adoption rate for diagnosing NIFTP, with North American pathologists diagnosing it more frequently than those in Europe and Asia/Oceania.
- - Significant differences exist in how pathologists assess nuclear features, especially for moderate changes, leading to regional variations in NIFTP diagnosis, with North American and European pathologists generally using lower thresholds for diagnosis compared to their counterparts in Asia/Oceania.
Background: Chromosomal rearrangements involving one of the NTRK genes result in oncogenic driver mutations in thyroid carcinoma (TC) and serve as a target for therapy. We compared the clinicopathologic features of thyroid carcinomas with NTRK fusions vs. thyroid neoplasms with other malignancy associated gene fusions within our institution.
View Article and Find Full Text PDFPerformance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
Cancer Cytopathol
May 2024
Article Synopsis
- Most thyroid nodules are benign, but differentiating between benign and malignant nodules can prevent unnecessary surgeries; this study focused on a genetic classifier's performance for indeterminate thyroid nodules in Southeast Asia.
- The study involved 132 patients and utilized ThyroSeq v3 for molecular testing on FNA samples, revealing that 56% of the nodules were histologically malignant, with varying mutation characteristics compared to North American patients.
- The genomic testing showed a 42% potential avoidance of surgery for patients with Bethesda category III-IV nodules, indicating that molecular testing was a stronger predictor of malignancy than traditional clinical factors.
Background: Differentiated high-grade thyroid carcinomas (DHGTCs) are a new diagnostic entity most recently defined in the 2022 World Health Organization's (WHO) Classification of Endocrine and Neuroendocrine Tumors. This new entity has been minimally described in the literature, and additional cases classified as such are missing.
Materials And Methods: Cases of DHGTCs diagnosed at our institution from 2012 to 2022 were identified, and the following were reviewed: cytologic and histologic diagnoses, ancillary testing, immunohistochemical staining, treatments, and patient outcomes.
Struma ovarii is a well-known ovarian teratoma made up of benign thyroid tissue. These lesions demonstrate variable, normal architecture and normal thyroid immunohistochemical staining with positivity for TTF1, PAX8, and thyroglobulin. Though most are benign, some of these lesions can also present with a malignant component.
View Article and Find Full Text PDF